

REMARKS

This preliminary amendment is being filed before the receipt of a First Office Action on the merits.

Support for the claims is found throughout the specification, including at page 20, lines 1-3 (polypeptide fragments), page 36, lines 7-9 (CD39L2 polypeptides), page 80, lines 19-32 (monoclonal and polyclonal antibodies, fragments thereof, hybridomas, detection), page 82, lines 24-30 (antibodies in detectably labeled form), page 87, lines 26-36 (methods for detecting polypeptides of invention) and page 88, lines 26-35 (kits).

It appears that the line numbers in the left-hand margin of the application as filed do not correspond precisely to each line. The line numbers designated in this document correspond to the actual lines as counted down from the top of each respective page.


If telephonic discussions with the undersigned would expedite allowance, the Examiner is invited to contact the undersigned at the number below.

No fees are thought to be due with the filing of this preliminary amendment. However, should any fees be deemed due, the Commissioner is authorized to charge any such fees to Marshall, Gerstein & Borun's Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By:


Michael F. Borun
Registration No. 25,447
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

November 26, 2001